Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD Trial
NCT06488105Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2024
- Primary completion
- Nov 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of rosuvastatin in hyperlipidemia, cardiovascular disease (CVD) and atherosclerosis (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Percent change in low-density lipoprotein cholesterol at 30 days. Started Aug 2024; status: recruiting.
02
Drugs
rosuvastatin
03
Conditions
hyperlipidemiacardiovascular disease (CVD)atherosclerosis
Beyond the preview
Go deeper on NCT06488105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488105.